Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims

British Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 255-267

  Karanges, Emily A ^a   Blanch, Bianca ^b   Buckley, Nicholas A ^b   Pearson, Sallie Anne ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

analgesics; Australia; dispensing; opioids; pharmacoepidemiology

Indexed keywords

BUPRENORPHINE; CODEINE; DEXTROPROPOXYPHENE; FENTANYL; HYDROMORPHONE; LONG ACTING DRUG; METHADONE; MORPHINE; OPIATE; OXYCODONE; PETHIDINE; SHORT ACTING ANALGESIC AGENT; TAPENTADOL; TRAMADOL;

ANALGESIA; ARTICLE; AUSTRALIA; CHRONIC PAIN; DRUG USE; HEALTH CARE SYSTEM; HUMAN; MEDICAL RECORD; PRESCRIPTION; PRIORITY JOURNAL; TRANSDERMAL PATCH;

EID: 84976597540     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12937     Document Type: Article

References (72)

1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013; 380: 2163–96.
2. Lalonde L, Choinière M, Martin É, Berbiche D, Perreault S, Lussier D. Costs of moderate to severe chronic pain in primary care patients – a study of the ACCORD Program. J Pain Res 2014; 7: 389–403.
3. Reid KJ, Harker J, Bala MM, Truyers C, Kellen E, Bekkering GE, et al. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin 2011; 27: 449–62.
4. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287–333.
5. Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: a review of the evidence. Clin J Pain 2008; 24: 469–78.
6. Michna E, Cheng WY, Korves C, Birnbaum H, Andrews R, Zhou Z, et al. Systematic literature review and meta-analysis of the efficacy and safety of prescription opioids, including abuse-deterrent formulations, in non-cancer pain management. Pain Med 2014; 15: 79–92.
7. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13: e58–68.
8. Melnikova I. Pain market. Nat Rev Drug Discov 2010; 9: 589–90.
9. Marcus DA. Epidemiology of cancer pain. Curr Pain Headache Rep 2011; 15: 231–4.
10. Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health pathways to prevention workshop. Ann Intern Med 2015; 162: 276–86.
11. Breivik H. Opioids in chronic non-cancer pain, indications and controversies. Eur J Pain 2005; 9: 127–30.
12. Sullivan MD, Howe CQ. Opioid therapy for chronic pain in the United States: promises and perils. Pain 2013; 154: S94–S100.
13. Frenk SM, Porter KS, Paulozzi LL. Prescription opioid analgesic use among adults: United States, 1999–2012. NCHS data brief, no. 189. Hyattsville, MD: National Centre for Health Statistics, 2015.
14. Zin C, Chen L-C, Knaggs R. Changes in trends and pattern of strong opioid prescribing in primary care. Eur J Pain 2014; 18: 1343–51.
15. International Narcotics Control Board (INCB). Report 2014 – Narcotic drugs: estimated world requirements for 2015; statistics for 2013. New York: United Nations, 2015.
16. Pain and Policy Studies Group. Opioid consumption motion chart. Madison: University of Wisconsin-Madison, 2015. Available at https://ppsg.medicine.wisc.edu/chart (last accessed 4 September 2015).
17. Hollingworth SA, Gray PD, Hall WD, Najman JM. Opioid analgesic prescribing in Australia: a focus on gender and age. Pharmacoepidemiol Drug Saf 2015; 24: 628–36.
18. Roxburgh A, Burns L, Drummer OH, Pilgrim J, Farrell M, Degenhardt L. Trends in fentanyl prescriptions and fentanyl-related mortality in Australia. Drug Alcohol Rev 2013; 32: 269–75.
19. Roxburgh A, Bruno R, Larance B, Burns L. Prescription of opioid analgesics and related harms in Australia. Med J Aust 2011; 195: 280–4.
20. Leong M, Murnion B, Haber P. Examination of opioid prescribing in Australia from 1992 to 2007. Intern Med J 2009; 39: 676–81.
21. Blanch B, Pearson S-A, Haber PS. An overview of the patterns of prescription opioid use, costs and related harms in Australia. Br J Clin Pharmacol 2014; 78: 1159–66.
22. Atluri S, Sudarshan G, Manchikanti L. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. Pain Physician 2014; 17: e119–28.
23. Mellish L, Karanges EA, Litchfield MJ, Schaffer AL, Blanch B, Daniels BJ, et al. The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers. BMC Res Notes 2015; 8: 634.
24. Australian Government Department of Health. Australian Statistics on Medicines 2011. Canberra: Commonwealth of Australia, 2013.
25. Australian Government Department of Health. Report on the collection of under co-payment data 2013–2014. Canberra, 2014. Available at http://www.pbs.gov.au/info/statistics/under-co-payment/ucp-data-report (last accessed 5 May 2015).
26. Royal Australasian College of Physicians. Prescription opioid policy: improving the management of chronic non-malignant pain and prevention of problems associated with prescription opioid use. Sydney: RACP, 2008.
27. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 2014. Oslo: World Health Organization, 2015.
28. Australian Bureau of Statistics. Australian Historical Population Statistics, 2014; table, Cat. no. 3105.0.65.001. Canberra: Australian Bureau of Statistics, 2014.
29. Australian Government Department of Health. PBS Publications archive. Canberra, 2015. Available at http://www.pbs.gov.au/info/publication/schedule/archive (last accessed 16 September 2015).
30. Pearson SA, Pesa N, Langton JM, Drew A, Faedo M, Robertson J. Studies using Australia's Pharmaceutical Benefits Scheme data for pharmacoepidemiological research: a systematic review of the published literature (1987–2013). Pharmacoepidemiol Drug Saf 2015; 24: 447–55.
31. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2 – guidance. Pain Physician 2012; 15: S67–116.
32. Cheung CW, Qiu Q, Choi S-W, Moore B, Goucke R, Irwin M. Chronic opioid therapy for chronic non-cancer pain: a review and comparison of treatment guidelines. Pain Physician 2014; 17: 401–14.
33. Ruscitto A, Smith B, Guthrie B. Changes in opioid and other analgesic use 1995–2010: Repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. Eur J Pain 2015; 19: 59–66.
34. Fischer B, Jones W, Rehm J. Trends and changes in prescription opioid analgesic dispensing in Canada 2005–2012: an update with a focus on recent interventions. BMC Health Serv Res 2014; 14: 90.
35. National Prescribing Service. Analgesic options for pain relief. MedicineWise News 2006; 47.
36. Australian Medicines Handbook 2015. Adelaide: Australian Medicines Handbook Pty Ltd, 2015.
37. Kenan K, Mack K, Paulozzi L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000–2010. Open Med 2012; 6: e41.
38. Steinman MA, Komaiko KD, Fung KZ, Ritchie CS. Use of opioids and other analgesics by older adults in the United States, 1999–2010. Pain Med 2014; 16: 319–27.
39. Hamunen K, Paakkari P, Kalso E. Trends in opioid consumption in the Nordic countries 2002–2006. Eur J Pain 2009; 13: 954–62.
40. International Narcotics Control Board (INCB). Report 2013 – Narcotic drugs: estimated world requirements for 2014; statistics for 2012. New York: United Nations, 2014.
41. British Pain Society, Faculty of Pain Medicine of the Royal College of Anaesthetists, Royal College of General Practitioners, Faculty of Addictions of the Royal College of Psychiatrists. Opioids for persistent pain. Summary on guidance on good practice from the British Pain Society. London: British Pain Society, 2010.
42. Analgesic Expert Group. Therapeutic Guidelines: Analgesic. Version 6. Melbourne: Therapeutic Guidelines Ltd, 2012.
43. Sullivan M. Will data destroy our faith in long-acting opioids? Pain 2014; 155: 843–4.
44. US Food and Drug Administration. FDA announces safety labeling changes and postmarket study requirements for extended-release and long-acting opioid analgesics. Press release, 2013. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm367726.htm (last accessed 16 September 2015).
45. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. Can Med Assoc J 2006; 174: 1589–94.
46. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010; 1: CD006605.
47. Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC. Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev 2013; 8: CD004959.
48. Harrison CM, Charles J, Henderson J, Britt H. Opioid prescribing in Australian general practice. Med J Aust 2012; 196: 380–1.
49. Hoy D, Bain C, Williams G, March L, Brooks P, Blyth F, et al. A systematic review of the global prevalence of low back pain. Arthritis Rheum 2012; 64: 2028–37.
50. Britt H, Miller G, Henderson J, Bayram C, Valenti L, Harrison C, et al. A decade of Australian general practice activity 2004–05 to 2013–14. Sydney: Sydney University Press, 2014.
51. Croft P, Blyth FM, van der Windt D. Chronic pain epidemiology: from aetiology to public health. New York: Oxford University Press, 2010.
52. Australian Bureau of Statistics. Characteristics of bodily pain. Canberra, 2012. Available at http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4841.0Chapter12011 (last accessed 8 September 2015).
53. Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain: a review of published literature. Ann Oncol 2008; 19: 1985–91.
54. Auret K, Schug SA. Underutilisation of opioids in elderly patients with chronic pain. Drugs Aging 2005; 22: 641–54.
55. Campbell CI, Weisner C, LeResche L, Ray GT, Saunders K, Sullivan MD, et al. Age and gender trends in long-term opioid analgesic use for noncancer pain. Am J Public Health 2010; 100: 2541–7.
56. Makris UE, Abrams RC, Gurland B, Reid MC. Management of persistent pain in the older patient: a clinical review. JAMA 2014; 312: 825–37.
57. Hollingworth SA, Symons M, Khatun M, Loveday B, Ballantyne S, Hall WD, et al. Prescribing databases can be used to monitor trends in opioid analgesic prescribing in Australia. Aust N Z J Public Health 2013; 37: 132–8.
58. National Drug and Alcohol Research Centre. A review of opioid prescribing in Tasmania: a blueprint for the future. Sydney: University of New South Wales, 2012.
59. Islam MM, McRae IS, Mazumdar S, Taplin S, McKetin R. Prescription opioid analgesics for pain management in Australia: twenty years of dispensing. Intern Med J 2015. doi:10.1111/imj.12966.
60. Drug Utilisation Sub-Committee (DUSC). Opioid analgesics: overview. Canberra: Australian Government Department of Health, 2014.
61. Tobin CL, Dobbin M, McAvoy B. Regulatory responses to over-the-counter codeine analgesic misuse in Australia, New Zealand and the United Kingdom. Aust N Z J Public Health 2013; 37: 483–8.
62. Nielsen S, Degenhardt L, Hoban B, Gisev N. Comparing opioids: a guide to estimating oral morphine equivalents (OME) in research. Sydney: National Drug and Alcohol Research Centre, 2014.
63. Hastie BA, Gilson AM, Maurer MA, Cleary JF. An examination of global and regional opioid consumption trends 1980–2011. J Pain Palliat Care Pharmacother 2014; 28: 259–75.
64. Svendsen K, Borchgrevink P, Fredheim O, Hamunen K, Mellbye A, Dale O. Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses. Palliat Med 2011; 25: 725–32.
65. Haegerich TM, Paulozzi LJ, Manns BJ, Jones CM. What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol Depend 2014; 145: 34–47.
66. Weisberg DF, Becker WC, Fiellin DA, Stannard C. Prescription opioid misuse in the United States and the United Kingdom: cautionary lessons. Int J Drug Policy 2014; 25: 1124–30.
67. Pharmacy Guild of Australia. Oxycontin reformulation – effective 1 April 2014. Canberra, 2014. Available at https://www.guild.org.au/news-page/2014/03/20/oxycontin-reformulation–effective-1-april-2014 (last accessed 5 August 2015).
68. Shand FL, Campbell G, Hall W, Lintzeris N, Cohen M, Degenhardt L. Real-time monitoring of Schedule 8 medicines in Australia: evaluation is essential. Med J Aust 2013; 198: 80–1.
69. Schatman ME, Webster LR. The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability. J Pain Res 2015; 8: 153–8.
70. Campbell G, Nielsen S, Bruno R, Lintzeris N, Cohen M, Hall W, et al. The Pain and Opioids IN Treatment study: characteristics of a cohort using opioids to manage chronic non-cancer pain. Pain 2015; 156: 231–42.
71. Rogers KD, Kemp A, McLachlan AJ, Blyth F. Adverse selection? A multi-dimensional profile of people dispensed opioid analgesics for persistent non-cancer pain. PLoS One 2013; 8: e80095.
72. Gadzhanova S, Bell JS, Roughead EE. What analgesics do older people use prior to initiating oxycodone for non-cancer pain? A retrospective database study. Drugs Aging 2013; 30: 921–6.